A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS)

• Principais autores: Linlin Tang (Autor), Cuicui Sun (Autor), Wenshan Liu (Autor), Haiyan Wu (Autor), Chuanhua Ding (Autor)
• Formato: Livro
• Publicado em: Frontiers Media S.A., 2024-02-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Background: Antibody-drug conjugates (ADCs) are a relatively new class of anticancer agents that use monoclonal antibodies to specifically recognize tumour cell surface antigens. However, off-target effects may lead to severe adverse events. This study evaluated the neurotoxicity of ADCs using the F...